Avadel Pharmaceuticals PLC at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone. Again, thanks for joining us for the next session. I'm Ami Fadia. I'm one of the biotech analysts here at Needham. It's my pleasure to be hosting the Avadel team for this session. Greg, Tom, Richard, thank you so much for joining us today.
Maybe what I'll do is start by requesting Greg to just kick it off with overview of kind of the recent updates to the company. You had the recent sort of financing as well as the upcoming decision from the FDA. So, if you could just sort of level set for listeners where we are. And then we'll jump to Q&A. (Conference instructions) With that, turn over to you, Greg.
Thanks, Ami. And as always, thank you for the opportunity to participate and be a part of this conference. Maybe I'll just start with the general commentary that some of our comments today may include forward-looking statements. And to the extent they do in our business is subject to risks and uncertainties that are described in our 10
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |